Obsessive-Compulsive DisorderVR-TMSNCT06442527
Using Virtual Reality Before Transcranial Magnetic Stimulation for the Treatment of OCD
A study testing Virtual Reality in people with Obsessive-Compulsive Disorder, run by Yale University at 1 site in United States.
Trial summary
This study will focus on the use of Virtual Reality (VR) technology in patients receiving treatment using Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD) Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obsessive-Compulsive Disorder
- What is being tested?
- Virtual Reality
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- May 2025to Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must be at least 18 years old
- Patients must have been clinically evaluated by a Yale Interventional Psychiatry Service physician who has deemed them appropriate to receive TMS for the treatment of OCD
- Ability and willingness, in the investigator's judgement, to comply with the study procedure and study requirements.
Who cannot join
- Hearing or visual impairment to the degree that would interfere with ability to see or hear VR content.
- Difficulty in understanding spoken or written English
- Pregnancy
- History of seizure disorder
- Unable to provide informed consent
- Dementia or other cognitive disorder or intellectual disability that would impair the subject's ability to understand the study procedure (per investigator judgment)
Show all 9Show fewer
- Any implanted medical device, risk of interference with which by the VR device in the investigator's judgment can put patient at additional undue risk.
- Any other medical or psychiatric comorbidity that the investigator judges would put the participant at additional undue risk due to study participation or would impair subject's ability to participate in the study.
- Was previously enrolled/randomized into the study
Trial locations and contacts
1 site in 1 country.
United States1 site
Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unit
New Haven, Connecticut, 06520
About this study
This study will focus on the use of Virtual Reality (VR) technology in patients receiving treatment using Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD)
- Conditions
- Obsessive-Compulsive Disorder
- Being tested
- Virtual Reality
- Keywords
- TMS, Transcranial Magnetic Stimulation, Virtual Reality, VR
- Medical subject headings
- Obsessive-Compulsive Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual RealityDevice
Virtual reality gear and content will be used prior to TMS session as part of the provocation items
| Study group | Role | What they receive |
|---|---|---|
| Treatment Group | Experimental | This single arm will include all participants of the study, who will all receive the intervention Receives: Device: Virtual Reality |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tolerability of VR treatment by qualitative assessment
Tolerability will be assessed by open-ended interview of the patient about their experience and any difficulty tolerating VR
Measured: Within 1 hour after each treatment session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2024
- Study startMay 2025 (estimated)
- Primary completionDec 2025 (estimated)
- Study completionDec 2025 (estimated)
Why it stopped: Study never initiaed.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obsessive-Compulsive DisorderStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sina Nikayin, MD, Principal investigator, Assistant Professor, Departement of Psychiatry, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06442527
- Sponsor's protocol ID
- 2000037937
- Acronym
- VR-TMS
- Status last verified
- May 2026
- First submitted
- 29 May 2024
- Last updated
- 27 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Using Virtual Reality Before Transcranial Magnetic Stimulation for the Treatment of OCD
- ClinicalTrials.gov ID
- NCT06442527
- Acronym / sponsor ID
- VR-TMS / 2000037937
- Conditions
- Obsessive-Compulsive Disorder
- Keywords
- TMS, Transcranial Magnetic Stimulation, Virtual Reality, VR
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Study never initiaed.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Study start
- May 2025 (estimated)
- Primary completion
- Dec 2025 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 4 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will focus on the use of Virtual Reality (VR) technology in patients receiving treatment using Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD)
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment Group | Experimental | Device: Virtual RealityThis single arm will include all participants of the study, who will all receive the intervention |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Participants must be at least 18 years old
- Patients must have been clinically evaluated by a Yale Interventional Psychiatry Service physician who has deemed them appropriate to receive TMS for the treatment of OCD
- Ability and willingness, in the investigator's judgement, to comply with the study procedure and study requirements.
Key exclusion criteria (9 listed)
- Hearing or visual impairment to the degree that would interfere with ability to see or hear VR content.
- Difficulty in understanding spoken or written English
- Pregnancy
- History of seizure disorder
- Unable to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Virtual RealityVirtual reality gear and content will be used prior to TMS session as part of the provocation items | Device | Treatment Group |
Primary outcome
Tolerability of VR treatment by qualitative assessment
Time frame: Within 1 hour after each treatment session
Tolerability will be assessed by open-ended interview of the patient about their experience and any difficulty tolerating VR
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2026.
- Individual participant dataSharing planned: No
Related trials for Obsessive-Compulsive Disorder
Not yet recruitingObservational study
Investigation of Obsessive-Compulsive Disorder in Patients With Elbow Epicondylitis
Lateral Epicondylitis, Medial Epicondylitis
Recruiting
Precision Analytic Research Methods in OCD
Obsessive Compulsive Disorder
Recruiting
Focused Ultrasound for Behavioral Health
Depression, Anxiety
Not yet recruiting
Linear Accelerator Radiosurgical Anterior Capsulotomy With Task-based fMRI Identification of PERSonalized and PrEdictiVE Biomarkers of REsponse in Treatment-Refractory Obsessive-Compulsive Disorder (PERSEVERE Trial)
Treatment-refractory Obsessive-compulsive Disorder (trOCD)
Recruiting
tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder
Obsessive-Compulsive Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sina Nikayin, MD principal investigator
Assistant Professor, Departement of Psychiatry, Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Virtual Reality in people with Obsessive-Compulsive Disorder, run by Yale University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 27 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tolerability of VR treatment by qualitative assessment (time frame: Within 1 hour after each treatment session). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2026.